Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019-2030

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods
3.7. Chimeric Antigen Receptor T-Cell Therapy (CAR-T)
3.7.1. History of Development
3.7.2. Anatomical Layout of CAR
3.7.2.1. Ectodomain
3.7.2.2. Transmembrane Domain
3.7.2.3. Endodomain
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration of CAR-T Cell Therapies
3.7.6. Case Study: CD19 CAR-T Cell Therapies
3.7.7. Other Important Biological Targets for CAR Development
3.7.8. Challenges Associated with CAR-T Cell Therapies
3.7.8.1. Competitive Risks
3.7.8.2. Clinical Risks
3.7.8.3. Regulatory Risks
3.7.8.4. Commercial Risks
3.8. T-Cell Receptor (TCR)-based Cell Therapy
3.8.1. History of Development
3.8.2. Anatomical Layout of TCR
3.8.3. Development of TCR for Therapy
3.8.4. Differences between CAR-T and TCR-based Therapies
3.9. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
3.9.1. History of Development
3.9.2. Development of TILs for Therapy
3.10. Key Challenges and Roadblocks

4.1. Chapter Overview
4.2. T-Cell Immunotherapies: Trends on Twitter
4.2.1. Historical Trend in Volume of Tweets
4.2.2. Trending Words / Phrases on Twitter
4.2.3. Most Popular Drugs on Twitter
4.2.4. Most Prolific Authors on Twitter
4.2.5. Most Popular Indications and Target Antigens

5.1. Chapter Overview
5.2. T-Cell Immunotherapies: Overall Market Overview
5.2.1. Analysis by Type of Product
5.2.2. Analysis by Type of Developer
5.2.3. Analysis by Phase of Development
5.2.4. Analysis by Target Oncological Indications
5.2.4.1. CAR-T Cell Immunotherapies: Popular Target Indications
5.2.4.2. TCR-based Immunotherapies: Popular Target Indications
5.2.4.3. TIL-based Immunotherapies: Popular Target Indications
5.2.5. Analysis by Popular Target Antigens (CAR-T Cell Therapies and TCR-based Therapies)
5.2.6. Analysis by Source of T-Cells
5.2.7. Analysis by Route of Administration
5.2.8. Key Industry Players: Analysis by Number of Therapies in Development
5.2.9. Key Non-Industry Players: Analysis by Number of Therapies in Development

6.1. Chapter Overview
6.2. T-Cell Immunotherapies: Competitive Analysis by Popular Target Antigens
6.2.1. Popular Targets Related to Hematological Malignancies
6.2.1.1. Competitive Landscape of CD19 CAR-T Cell Immunotherapies
6.2.1.2. Clinical Trial Results of Prominent CD19 CAR-T Cell Immunotherapies
6.2.1.3. Competitive Landscape of BCMA CAR-T Cell Immunotherapies
6.2.1.4. Clinical Trial Results of Prominent BCMA CAR-T Cell Immunotherapies
6.2.2. Solid Tumors: Popular Targets
6.2.2.1. Competitive Landscape of Meso CAR-T Cell Immunotherapies
6.2.2.2. Clinical Trial Results of Prominent of Meso CAR-T Cell Immunotherapies
6.2.2.3. Competitive Landscape of GD2 CAR-T Cell Immunotherapies
6.2.2.4. Clinical Trial Results of Prominent GD2 CAR-T Cell Immunotherapies
6.3. T-Cell Immunotherapies: Key Opinion Leaders
6.3.1. CAR-T Cell Therapies: Key Opinion Leaders
6.3.2. CAR-T Cell Therapies: Most Prominent Key Opinion Leaders
6.3.3. TCR-based Therapies: Key Opinion Leaders
6.3.4. TCR-based Therapies: Most Prominent Key Opinion Leaders
6.3.5. TIL-based Therapies: Key Opinion Leaders
6.3.6. TIL-based Therapies: Most Prominent Key Opinion Leaders
6.4. T-Cell Immunotherapies: CAR Construct Analysis
6.4.1. Analysis by Generation of CAR
6.4.2. Analysis by Type of scFv Antibody
6.4.3. Analysis by Type of Vector
6.4.4. Analysis by Type of Co-Stimulatory Domain(s)

7.1. Chapter Overview
7.2. CAR-T Cell Therapies: Clinical Trial Analysis
7.2.1. Methodology
7.2.2. Analysis by Trial Registration Year
7.2.3. Geographical Analysis by Number of Registered Trials
7.2.4. Case Study: CAR-T Cell Therapy Market in China
7.2.4.1. Factors Contributing to the Growth of CAR-T Cell Therapy Trials in China

8.1. Chapter Overview
8.2. KYMRIAH® / Tisagenlecleucel / CTL019 (Novartis)
8.2.1. Therapy Overview
8.2.2. Current Development Status
8.2.3. Key Clinical Trial Results
8.2.4. Dosage Regimen, Price and Manufacturing
8.3. YESCARTA®/ Axicabtagene Ciloleucel / KTE-C19 (Kite Pharma)
8.3.1. Therapy Overview
8.3.2. Current Development Status
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen, Price and Manufacturing
8.4. JCAR (Juno Therapeutics)
8.4.1. Therapy Overview
8.4.1.1. JCAR014
8.4.1.2. JCAR017
8.4.1.3. JCAR018
8.4.1.4. JCAR020
8.4.1.5. JCAR023
8.4.1.6. JCAR024
8.4.1.7. JCARH125
8.4.2. Current Development Status
8.4.3. Key Clinical Trial Results
8.4.4. Dosage Regimen and Manufacturing
8.5. bb2121 (bluebird bio / Celgene)
8.5.1. Therapy Overview
8.5.2. Current Development Status
8.5.3. Key Clinical Trial Results
8.5.4. Dosage Regimen and Manufacturing
8.6. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen Biotech)
8.6.1. Therapy Overview
8.6.2. Current Development Status
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing
8.7. CD19 CAR-T Cell Therapy (Takara Bio)
8.7.1. Therapy Overview
8.7.2. Current Development Status
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing
8.8. Dual Targeting CAR-T Cell Therapy (Autolus)
8.8.1. Therapy Overview
8.8.2. Current Development Status
8.8.3. Key Clinical Trial Results
8.8.4. Dosage Regimen and Manufacturing
8.9. CAR-T Cell Therapies (Sinobioway Cell Therapy / The First Affiliated Hospital of Anhui Medical University)
8.9.1. Therapy Overview
8.9.2. Current Development Status
8.9.3. Dosage Regimen and Manufacturing

9.1. Chapter Overview
9.2. SPEAR T-Cells (Adaptimmune / GlaxoSmithKline)
9.2.1. Therapy Overview
9.2.1.1. SPEAR T-Cells Technology Platform
9.2.1.1. NY-ESO SPEAR T-Cell Therapy
9.2.1.2. MAGE-A10 T-Cell Therapy
9.2.1.3. MAGE-A4 T-Cell Therapy
9.2.1.4. AFP T-Cell Therapy
9.2.2. Current Development Status
9.2.3. Key Clinical Trial Results
9.2.4. Dosage Regimen and Manufacturing
9.3. IMCgp100 (Immunocore)
9.3.1. Therapy Overview
9.3.2. Current Development Status
9.3.3. Key Clinical Trial Results
9.3.4. Dosage Regimen and Manufacturing
9.4. ALT-801 (Altor BioScience)
9.4.1. Therapy Overview
9.4.2. Current Development Status
9.4.3. Key Clinical Trial Results
9.4.4. Dosage Regimen
9.4.5. Patent Portfolio
9.5. JTCR016 (Juno Therapeutics)
9.5.1. Therapy Overview
9.5.2. Current Development Status
9.5.3. Key Clinical Trial Results
9.5.4. Dosage Regimen and Manufacturing
9.6. CMD-602 / WT1 TCR Therapy (Cell Medica)
9.6.1. Therapy Overview
9.6.2. History of Development
9.6.3. Current Development Status
9.6.4. Key Clinical Trial Results
9.6.5. Dosage Regimen and Manufacturing
9.7. TBI-1301 (Takara Bio)
9.7.1. Therapy Overview
9.7.2. Current Development Status
9.7.3. Key Clinical Trial Results
9.7.4. Dosage Regimen and Manufacturing

10.1. Chapter Overview
10.2. Autologous TIL Therapies (Iovance Biotherapeutics)
10.2.1. Therapy Overview
10.2.2. Current Development Status
10.2.2.1. LN-144
10.2.2.2. LN-145
10.2.3. Key Clinical Trial Results
10.2.4. Dosage Regimen and Manufacturing
10.2.5. Patent Portfolio
10.3. TIL (Nantes University Hospital)
10.3.1. Therapy Overview
10.3.2. Current Development Status
10.3.3. Key Clinical Trial Results
10.3.4. Dosage Regimen and Manufacturing
10.3.5. Patent Portfolio
10.4. TIL (Netherlands Cancer Institute)
10.4.1. Therapy Overview
10.4.2. Current Development Status
10.4.3. Key Clinical Trial Results
10.4.4. Dosage Regimen and Manufacturing
10.4.5. Patent Portfolio

11.1. Chapter Overview
11.2. Haematological Malignancies
11.2.1. Leukaemia and Lymphoma
11.2.1.1. Leukaemia: Introduction and Epidemiology
11.2.1.1.1. Acute Myeloid Leukemia (AML)
11.2.1.1.2. Chronic Myeloid Leukemia (CML)
11.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
11.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
11.2.1.2. Lymphoma: Introduction and Epidemiology
11.2.1.3. Current Treatment Landscape
11.2.1.3.1. Targeted Therapies
11.2.1.4. T-Cell Immunotherapy and Affiliated Research Landscape
11.2.1.4.1. CAR-T Cell Therapies and Leukemia / Lymphoma
11.2.1.4.2. TCR-based Therapies and Leukemia / Lymphoma
11.2.1.4.3. TIL-based Therapies and Leukemia
11.2.2. Multiple Myeloma
11.2.2.1. Introduction and Epidemiology
11.2.2.2. Current Treatment Landscape
11.2.2.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3. Solid Tumors
11.3.1. Metastatic Melanoma
11.3.1.1. Introduction and Epidemiology
11.3.1.2. Current Treatment Landscape
11.3.1.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.1.3.1. CAR-T Cell Therapies and Metastatic Melanoma
11.3.1.3.2. TCR-based Therapies and Metastatic Melanoma
11.3.1.3.3. TIL-based Therapies and Metastatic Melanoma
11.3.2. Lung Cancer
11.3.2.1. Introduction and Epidemiology
11.3.2.2. Current Treatment Landscape
11.3.2.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.3. Pancreatic Cancer
11.3.3.1. Introduction and Epidemiology
11.3.3.2. Current Treatment Landscape
11.3.3.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.3.3.1. CAR-T Cell Therapies and Pancreatic Cancer
11.3.3.3.2. TCR-based Therapies and Pancreatic Cancer
11.3.3.3.3. TIL-based Therapies and Pancreatic Cancer
11.3.4. Liver Cancer
11.3.4.1. Current Treatment Landscape
11.3.4.2. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.4.3. CAR-T Cell Therapies and Liver Cancer
11.3.4.3.1. TCR-based Therapies and Liver Cancer
11.3.4.3.2. TIL-based Therapies and Liver Cancer
11.3.5. Breast Cancer
11.3.5.1. Introduction and Epidemiology
11.3.5.2. Current Treatment Landscape
11.3.5.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.5.3.1. CAR-T Cell Therapies and Breast Cancer
11.3.5.3.2. TCR-based Therapies and Breast Cancer
11.3.5.3.3. TIL-based Therapies and Breast Cancer
11.3.6. Ovarian Cancer
11.3.6.1. Introduction and Epidemiology
11.3.6.2. Current Treatment Landscape
11.3.6.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.6.3.1. CAR-T Cell Therapies and Ovarian Cancer
11.3.6.3.2. TCR-based Therapies and Ovarian Cancer
11.3.6.3.3. TIL-based Therapies and Ovarian Cancer
11.3.7. Bladder Cancer
11.3.7.1. Introduction and Epidemiology
11.3.7.2. Current Treatment Landscape
11.3.7.3. T-Cell Immunotherapy and Affiliated Research Landscape
11.3.8. Kidney Cancer
11.3.8.1. Introduction and Epidemiology
11.3.8.2. Current Treatment Landscape
11.3.8.3. T-Cell Immunotherapy and Affiliated Research Landscape

12.1. Chapter Overview
12.2. Genome Editing Technologies
12.2.1. Applications of Genome Editing Technologies
12.2.2. Emerging Technology Platforms for T-Cell Therapy Development and Production
12.2.2.1. CRISPR / Cas9 System
12.2.2.1.1. Key Components and Function
12.2.2.1.2. Mechanism of Action
12.2.2.1.3. Targeting Efficiency and Challenges
12.2.2.1.4. Next-GEN CRISPR Technology
12.2.2.1.5. Technology Providers
12.2.2.1.5.1. Editas Medicine
12.2.2.1.5.2. Intellia Therapeutics
12.2.2.1.5.3. CRISPR Therapeutics
12.2.2.1.5.4. Beam Therapeutics
12.2.2.1.5.5. Gracell Biotechnologies
12.2.2.2. TALENs
12.2.2.2.1. Key Components and Function
12.2.2.2.2. Mechanism of Action
12.2.2.2.3. Advantages and Challenges
12.2.2.2.4. Technology Providers
12.2.2.2.4.1. Cellectis
12.2.2.2.4.2. Editas Medicine
12.2.2.3. megaTAL
12.2.2.3.1. Technology Providers
12.2.2.3.1.1. bluebird bio
12.2.2.4. Zinc Finger Nuclease
12.2.2.4.1. Technology Providers
12.2.2.4.1.1. Sangamo Therapeutics
12.3. Designing T-Cell Therapies with Improved Characteristics
12.3.1. Technologies for Targeting Multiple Types of Cancers
12.3.1.1. Antibody Coupled T-Cell Receptor
12.3.1.1.1. Unum Therapeutics
12.3.1.2. NKR-T Platform
12.3.1.2.1. Celyad
12.3.1.2.2. Glycostem
12.3.2. Technologies for Improving Therapeutic Safety
12.3.2.1. Armored CAR and EGFRt Technology
12.3.2.1.1. Juno Therapeutics
12.3.2.2. RheoSwitch Therapeutic System
12.3.2.2.1. Intrexon
12.3.2.3. Inducible Caspase 9 Safety Switch
12.3.2.3.1. Bellicum Pharmaceuticals
12.3.2.3.1.1. CaspaCIDe® Technology
12.3.2.3.1.2. CIDeCAR® Technology
12.3.2.3.1.3. GoCAR-T® Technology
12.3.2.4. On-Off Switch, Multiple Companies
12.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
12.3.2.4.2. On-Off Switch (Theravectys)
12.3.3.5. Other Technologies to Improve CAR-T Safety
12.3.3.6. Allogeneic Technologies
12.3.3.6.1. CIK CAR-T™ Cells (Formula Pharmaceuticals)
12.3.3.6.2. Allogeneic Platform (Celyad)
12.3.3.6.3. Allogeneic Platform (Cellectis)

13.1. Chapter Overview
13.2. Partnership Models
13.3. T-Cell Immunotherapies: List of Partnerships and Collaborations
13.3.1. Analysis by Year of Partnership
13.3.2. Analysis by Type of Partnership
13.3.3. Analysis by Type of Partnership and Type of Product
13.3.4. Analysis by Type of Industry and Type of Product
13.3.5. Analysis by Individual Products
13.3.6. Most Active Industry Players: Analysis by Number of Partnerships
13.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
13.3.8. Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements
13.3.9. Regional Analysis
13.3.10. Intercontinental and Intracontinental Agreements

14.1. Chapter Overview
14.2. Types of Funding
14.3. T-Cell Immunotherapies: Funding and Investment Analysis
14.3.1. Analysis by Number of Instances
14.3.2. Analysis by Amount Invested
14.3.3. Analysis by Type of Funding
14.3.4. Analysis by Amount Invested across Different Types of Therapies
14.3.5. Most Active Players: Analysis by Number of Instances
14.3.6. Most Active Investors: Analysis by Number of Instances
14.3.7. Regional Analysis

15.1. Chapter Overview
15.2. Other T-Cell Immunotherapies
15.2.1. Analysis by Phase of Development
15.2.2. Analysis by Target Therapeutic Area
15.2.3. Analysis by Type of Cells
15.2.4. Analysis by Source of T-Cells
15.3. Treg Cell Therapy
15.3.1. Caladrius Biosciences
15.3.2. TRACT Therapeutics
15.3.3. Cellenkos
15.3.4. Other Companies
15.4. T-Cell-based Vaccines
15.4.1. Immunovative Therapies
15.4.2. TVAX Biomedical
15.5. Virus-Driven T-Cell Therapy
15.5.1. Atara Biotherapeutics
15.5.2. bluebird bio
15.5.3. Cell Medica
15.5.4. Eutilex
15.5.5. Tessa Therapeutics
15.5.6. ViGenCell
15.6. Fucosylated T-Cell Therapy
15.6.1. Targazyme
15.7. PD-1 Knockout Engineered T-Cell Therapy
15.7.1. Chengdu MedGenCell
15.7.2. Anhui Kedgene Biotechnology
15.8. TAC-T Cell Therapy
15.8.1. Triumvira Immunologics
15.9. Gama Delta T-Cell Therapy
15.9.1. GammaCell Bio-Technologies
15.9.2. TC Biopharm

16.1. Chapter Overview
16.2. Cell Therapy Manufacturing
16.3. Cell Therapy Manufacturing Models
16.3.1. Centralized Manufacturing
16.3.2. Decentralized Manufacturing
16.4. Scalability of Cell Therapy Manufacturing Processes
16.4.1. Scale-up
16.4.2. Scale-out
16.5. Types of Cell Therapy Manufacturers
16.6. Key Challenges Related to Manufacturing Cell Therapies
16.7. Important Factors for Cell Therapy Manufacturing
16.7.1. Cell Characterization
16.7.2. Cost of Goods
16.8. Automation of Cell Therapy Manufacturing Processes
16.9. Cell Therapy Manufacturing Supply Chain
16.10. Companies with In-House Capabilities
16.11. Contract Manufacturers
16.12. Regulatory Landscape

17.1. Chapter Overview
17.2. Factors Contributing to the High Price of Cell / Gene Therapies
17.3. Pricing Models for T-Cell Immunotherapies
17.3.1. Based on Associated Costs
17.3.2. Based on Availability of Competing Products
17.3.3. Based on Patient Segment
17.3.4. Based on the Opinions of Industry Experts
17.4. Reimbursement-related Considerations For T-Cell Immunotherapies
17.4.1. Case Study: The National Institute for Health and Care Excellence’s (NICE) Appraisal of CAR-T Therapies

18.1. Chapter Overview
18.2. Scope and Limitations
18.3. Key Assumptions and Forecast Methodology
18.4. Overall T-Cell Immunotherapies Market, 2019-2030
18.4.1. T-Cell Immunotherapies Market: Distribution by Type of Therapy
18.4.2. T-Cell Immunotherapies Market: Distribution by Target Indication
18.4.3. T-Cell Immunotherapies Market: Distribution by Target Antigen
18.4.4. T-Cell Immunotherapies Market: Distribution by Key Players
18.4.5. T-Cell Immunotherapies Market: Distribution by Geography
18.5. T-Cell Immunotherapies Market: Value Creation Analysis
18.6. Overall CAR-T Cell Therapies Market, 2019-2030
18.6.1. CAR-T Cell Therapies Market: Distribution by Target Indication
18.6.2. CAR-T Cell Therapies Market: Distribution by Target Antigen
18.6.3. CAR-T Cell Therapies Market: Distribution by Key Players
18.6.4. CAR-T Cell Therapies Market: Distribution by Geography
18.6.5. Product Wise Sales Forecast
18.6.5.1. KYMRIAH® (Novartis)
18.6.5.1.1. Target Patient Population
18.6.5.1.2. Sales Forecast (USD Million)
18.6.5.1.3. Net Present Value (USD Million)
18.6.5.1.4. Value Creation Analysis
18.6.5.2. YESCARTA® (Gilead Sciences)
18.6.5.2.1. Target Patient Population
18.6.5.2.2. Sales Forecast (USD Million)
18.6.5.2.3. Net Present Value (USD Million)
18.6.5.2.4. Value Creation Analysis
18.6.5.3. bb2121 (bluebird bio / Celgene)
18.6.5.3.1. Target Patient Population
18.6.5.3.2. Sales Forecast (USD Million)
18.6.5.3.3. Net Present Value (USD Million)
18.6.5.3.4. Value Creation Analysis
18.6.5.4. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen)
18.6.5.4.1. Target Patient Population
18.6.5.4.2. Sales Forecast (USD Million)
18.6.5.4.3. Net Present Value (USD Million)
18.6.5.4.4. Value Creation Analysis
18.6.5.5. MB-CART19.1 (Miltenyi Biotec)
18.6.5.5.1. Target Patient Population
18.6.5.5.2. Sales Forecast (USD Million)
18.6.5.5.3. Net Present Value (USD Million)
18.6.5.5.4. Value Creation Analysis
18.6.5.6. CD19 CAR-T (Sinobioway Cell Therapy)
18.6.5.6.1. Target Patient Population
18.6.5.6.2. Sales Forecast (USD Million)
18.6.5.6.3. Net Present Value (USD Million)
18.6.5.6.4. Value Creation Analysis
18.6.5.7. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec)
18.6.5.7.1. Target Patient Population
18.6.5.7.2. Sales Forecast (USD Million)
18.6.5.7.3. Net Present Value (USD Million)
18.6.5.7.4. Value Creation Analysis
18.6.5.8. AUTO2 (Autolus)
18.6.5.8.1. Target Patient Population
18.6.5.8.2. Sales Forecast (USD Million)
18.6.5.8.3. Net Present Value (USD Million)
18.6.5.8.4. Value Creation Analysis
18.6.5.9. AUTO3 (Autolus)
18.6.5.9.1. Target Patient Population
18.6.5.9.2. Sales Forecast (USD Million)
18.6.5.9.3. Net Present Value (USD Million)
18.6.5.9.4. Value Creation Analysis
18.6.5.10. GPC3 CAR-T (Shanghai GeneChem)
18.6.5.10.1. Target Patient Population
18.6.5.10.2. Sales Forecast (USD Million)
18.6.5.10.3. Net Present Value (USD Million)
18.6.5.10.4. Value Creation Analysis
18.6.5.11. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology)
18.6.5.11.1. Target Patient Population
18.6.5.11.2. Sales Forecast (USD Million)
18.6.5.11.3. Net Present Value (USD Million)
18.6.5.11.4. Value Creation Analysis
18.6.5.12. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology)
18.6.5.12.1. Target Patient Population
18.6.5.12.2. Sales Forecast (USD Million)
18.6.5.12.3. Net Present Value (USD Million)
18.6.5.12.4. Value Creation Analysis
18.6.5.13. CD19 CAR-T (Shanghai Bioray Laboratory)
18.6.5.13.1. Target Patient Population
18.6.5.13.2. Sales Forecast (USD Million)
18.6.5.13.3. Net Present Value (USD Million)
18.6.5.13.4. Value Creation Analysis
18.6.5.14. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
18.6.5.14.1. Target Patient Population
18.6.5.14.2. Sales Forecast (USD Million)
18.6.5.14.3. Net Present Value (USD Million)
18.6.5.14.4. Value Creation Analysis
18.6.5.15. PCAR-019 (PersonGen BioTherapeutics)
18.6.5.15.1. Target Patient Population
18.6.5.15.2. Sales Forecast (USD Million)
18.6.5.15.3. Net Present Value (USD Million)
18.6.5.15.4. Value Creation Analysis
18.6.5.16. TBI-1501 (Takara Bio)
18.6.5.16.1. Target Patient Population
18.6.5.16.2. Sales Forecast (USD Million)
18.6.5.16.3. Net Present Value (USD Million)
18.6.5.16.4. Value Creation Analysis
18.6.5.17. IM19 CAR-T Cell Therapy (Beijing Immunochina Medical Science & Technology)
18.6.5.17.1. Target Patient Population
18.6.5.17.2. Sales Forecast (USD Million)
18.6.5.17.3. Net Present Value (USD Million)
18.6.5.17.4. Value Creation Analysis
18.6.5.18. CCT301 CAR-T Cell Therapy (Shanghai Sinobioway Sunterra Biotech)
18.6.5.18.1. Target Patient Population
18.6.5.18.2. Sales Forecast (USD Million)
18.6.5.18.3. Net Present Value (USD Million)
18.6.5.18.4. Value Creation Analysis
18.6.5.19. BinD19 (Shenzhen BinDeBio)
18.6.5.19.1. Target Patient Population
18.6.5.19.2. Sales Forecast (USD Million)
18.6.5.19.3. Net Present Value (USD Million)
18.6.5.19.4. Value Creation Analysis
18.6.5.20. CARCIK-CD19 (Formula Pharmaceuticals)
18.6.5.20.1. Target Patient Population
18.6.5.20.2. Sales Forecast (USD Million)
18.6.5.20.3. Net Present Value (USD Million)
18.6.5.20.4. Value Creation Analysis
18.6.5.21. EGFR CART Cell Therapy (The Beijing Pregene Science and Technology)
18.6.5.21.1. Target Patient Population
18.6.5.21.2. Sales Forecast (USD Million)
18.6.5.21.3. Net Present Value (USD Million)
18.6.5.21.4. Value Creation Analysis
18.6.5.22. Anti-MUC1 CAR-T Cell Therapy (Guangzhou Anjie Biomedical Technology)
18.6.5.22.1. Target Patient Population
18.6.5.22.2. Sales Forecast (USD Million)
18.6.5.22.3. Net Present Value (USD Million)
18.6.5.22.4. Value Creation Analysis
18.7. Overall TCR-based Therapies Market
18.7.1. TCR-based Therapies Market: Distribution by Target Indication
18.7.2. TCR-based Therapies Market: Distribution by Target Antigen
18.7.3. TCR-based Therapies Market: Distribution by Key Players
18.7.4. TCR-based Therapies Market: Distribution by Geography
18.7.6. Product Wise Sales Forecast
18.7.6.1. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck)
18.7.6.1.1. Target Patient Population
18.7.6.1.2. Sales Forecast (USD Million)
18.7.6.1.3. Net Present Value (USD Million)
18.7.6.1.4. Value Creation Analysis
18.7.6.2. IMCgp100 (Immunocore)
18.7.6.2.1. Target Patient Population
18.7.6.2.2. Sales Forecast (USD Million)
18.7.6.2.3. Net Present Value (USD Million)
18.7.6.2.4. Value Creation Analysis
18.7.6.3. TBI-1301 (Takara Bio)
18.7.6.3.1. Target Patient Population
18.7.6.3.2. Sales Forecast (USD Million)
18.7.6.3.3. Net Present Value (USD Million)
18.7.6.3.4. Value Creation Analysis
18.7.6.4. ALT-801 (Altor Bioscience)
18.7.6.4.1. Target Patient Population
18.7.6.4.2. Sales Forecast (USD Million)
18.7.6.4.3. Net Present Value (USD Million)
18.7.6.4.4. Value Creation Analysis
18.7.6.5. JTCR016 (Juno Therapeutics)
18.7.6.5.1. Target Patient Population
18.7.6.5.2. Sales Forecast (USD Million)
18.7.6.5.3. Net Present Value (USD Million)
18.7.6.5.4. Value Creation Analysis
18.7.6.6. LioCyx (Lion TCR)
18.7.6.6.1. Target Patient Population
18.7.6.6.2. Sales Forecast (USD Million)
18.7.6.6.3. Net Present Value (USD Million)
18.7.6.6.4. Value Creation Analysis
18.8. Overall TIL-based Therapies Market
18.8.1. TIL-based Therapies Market: Distribution by Target Indication
18.8.3. TIL-based Therapies Market: Distribution by Key Players
18.8.4. TIL-based Therapies Market: Distribution by Geography
18.8.5. Product Wise Sales Forecast
18.8.5.1. TILs (Nantes University Hospital)
18.8.5.1.1. Target Patient Population
18.8.5.1.2. Sales Forecast (USD Million)
18.8.5.1.3. Net Present Value (USD Million)
18.8.5.1.4. Value Creation Analysis
18.8.5.2. TILs (Netherlands Cancer Institute)
18.8.5.2.1. Target Patient Population
18.8.5.2.2. Sales Forecast (USD Million)
18.8.5.2.3. Net Present Value (USD Million)
18.8.5.2.4. Value Creation Analysis
18.8.5.3. Lifileucel (LN-144) (Iovance Biotherapeutics)
18.8.5.3.1. Target Patient Population
18.8.5.3.2. Sales Forecast (USD Million)
18.8.5.3.3. Net Present Value (USD Million)
18.8.5.3.4. Value Creation Analysis
18.8.5.4. LN-145 (Iovance Biotherapeutics)
18.8.5.4.1. Target Patient Population
18.8.5.4.2. Sales Forecast (USD Million)
18.8.5.4.3. Net Present Value (USD Million)
18.8.5.4.4. Value Creation Analysis
18.8.5.5. LTX-315 and TILs (Lytix Biopharma)
18.8.5.5.1. Target Patient Population
18.8.5.5.2. Sales Forecast (USD Million)
18.8.5.5.3. Net Present Value (USD Million)
18.8.5.5.4. Value Creation Analysis

19.1. Chapter Overview
19.2. Channels used for Promotional Campaigns
19.3. Summary of Product Website Analysis
19.4. Summary of Patient Support Services and Informative Downloads
19.5. KYMRIAH®: Promotional Analysis
19.5.1. Drug Overview
19.5.2. Product Website Analysis
19.5.2.1. Messages for Healthcare Professionals
19.5.2.2. Messages for Patients
19.5.3. Patient Support Services and Informative Downloads
19.5.4. Other Promotional Activities
19.5.4.1. Presence in Conferences
19.6. YESCARTA®: Promotional Analysis
19.6.1. Drug Overview
19.6.2. Product Website Analysis
19.6.2.1. Messages for Healthcare Professionals
19.6.2.2. Messages for Patients
19.6.3. Patient Support Services and Informative Downloads
19.6.4. Other Promotional Activities
19.6.4.1. Presence in Conferences

20.1. Chapter Overview
20.2. Adaptimmune Therapeutics
20.3. Autolus
20.4. bluebird bio
20.5. CARsgen Therapeutics
20.6. Celgene
20.7. Cell Medica
20.8. Cellectis
20.9. Cellular Biomedicine Group
20.10. Immunocore
20.11. Innovative Cellular Therapeutics
20.12. Iovance Biotherapeutics
20.13. Kite Pharma
20.14. Lion TCR
20.15. Noile-Immune Biotech
20.16. Novartis
20.17. Shanghai GeneChem
20.18. Sinobioway Cell Therapy
20.19. Takara Bio
20.20. Unum Therapeutics
20.21. ZIOPHARM Oncology

21.1. Chapter Overview
21.2. Key Takeaways

22.1. Chapter Overview
22.2. Cell Therapies
22.2.1 Interview Transcript: Tim Oldham, Chief Executive Officer
22.3. Glycostem Therapeutics
22.3.1 Interview Transcript: Troels Jordansen, Chief Executive Officer
22.4. Gracell Biotechnologies
22.4.1 Interview Transcript: Wei (William) Cao, Chief Executive Officer
22.5. Lion TCR
22.5.1 Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
22.6. TxCell
22.6.1 Interview Transcript: Miguel Forte, Chief Operating Officer
22.7. Kite Pharma
22.7.1 Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
22.8. Celyad
22.8.1 Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys
22.9. Iovance Biotherapeutics
22.9.1 Interview Transcript: Peter Ho, Director, Process Development
22.10. Waisman Biomanufacturing
22.10.1 Interview Transcript: Brian Dattilo, Manager of Business Development
22.11. Theravectys
22.11.1 Interview Transcript: Aino Kalervo, Competitive Intelligence Manager, Strategy & Business Development
22.12. Changhai Hospital
22.12.1 Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology
22.13. University of Colorado
22.13.1 Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

Figure 3.1. Pillars of Cancer Therapy
Figure 3.2. Difference between Active and Passive Immunotherapies
Figure 3.3. Difference between Specific and Non-Specific Immunotherapies
Figure 3.4. Strategies Employed for the Redirection of T-Cells
Figure 3.5. T-Cell Manufacturing: General Procedure
Figure 3.6. Historical Development of CAR-T cells
Figure 3.7. Structure of Chimeric Antigen Receptor
Figure 3.8. Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9. CAR-T Cell Therapies: Development Process
Figure 3.10. Challenges Associated with CAR-T Cell Therapies
Figure 3.11. TCR-based Therapies: Development Process
Figure 3.12. TIL-based Therapies: Development Process
Figure 3.13. T-Cell Immunotherapies: Benefits and Key Challenges
Figure 4.1. Social Media Analysis: Historical Trend on Twitter, January 2012-April 2019
Figure 4.2. Social Media Analysis: Trending Words / Phrases on Twitter
Figure 4.3. Social Media Analysis: Most Popular Drug Candidates on Twitter
Figure 4.4. Social Media Analysis: Most Prolific Authors on Twitter
Figure 4.5. Social Media Analysis: Average Number of Likes, Re-tweets and Comments Related to T-cell Immunotherapy
Figure 4.6. Social Media Analysis: Most Popular Indications and Target Antigen
Figure 5.1. T-Cell Immunotherapies: Analysis by Type of Product
Figure 5.2. T-Cell Immunotherapies: Analysis by Type of Developer
Figure 5.3. T-Cell Immunotherapies: Analysis by Type of Developer and Type of Product
Figure 5.4. T-Cell Immunotherapies: Analysis by Phase of Development
Figure 5.5. T-Cell Immunotherapies: Analysis by Phase of Development and Type of Product
Figure 5.6. T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Figure 5.7. T-Cell Immunotherapies: Analysis by Target Therapeutic Area and Type of Product
Figure 5.8. T-Cell Immunotherapies: Analysis by Popular Target Indications
Figure 5.9. CAR-T Cell Immunotherapies: Analysis by Popular Target Indications
Figure 5.10. TCR-based Immunotherapies: Analysis by Popular Target Indications
Figure 5.11. TIL-based Immunotherapies: Analysis by Popular Target Indications
Figure 5.12. CAR-T Cell Immunotherapies: Analysis by Target Antigen
Figure 5.13. TCR-based Immunotherapies: Analysis by Target Antigen
Figure 5.14. T-Cell Immunotherapies: Analysis by Source of T-Cells
Figure 5.15. T-Cell Immunotherapies: Analysis by Source of T-Cells and Type of Product
Figure 5.16. T-Cell Immunotherapy Developer Landscape: Distribution by Source of T-Cells and Type of Product
Figure 5.17. T-Cell Immunotherapies: Analysis by Route of Administration
Figure 5.18. T-Cell Immunotherapies: Analysis by Route of Administration and Type of Product
Figure 5.19. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 5.20. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 5.21. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Figure 5.22. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Figure 6.1. T-Cell Immunotherapies: Popular Targets in Hematological Malignancies
Figure 6.2. T-Cell Immunotherapies: Popular Targets in Solid Tumor
Figure 6.3. CAR-T Cell Immunotherapies: Geographical Distribution of Key Opinion Leaders
Figure 6.4. CAR-T Cell Immunotherapies: Prominent Key Opinion Leaders
Figure 6.5. TCR-based Immunotherapies: Geographical Distribution of Key Opinion Leaders
Figure 6.6. TCR-based Immunotherapies: Prominent Key Opinion Leaders
Figure 6.7. TIL-based Immunotherapies: Geographical Distribution of Key Opinion Leaders
Figure 6.8. TCR-based Immunotherapies: Prominent Key Opinion Leaders
Figure 6.9. CAR-Construction: Analysis by Generation of CAR-T Therapies
Figure 6.10. CAR-Construction: Analysis by Type of scFv Antibody used in CAR-T Therapies
Figure 6.11. CAR-Construction: Analysis by Type of Vector
Figure 6.12. CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Figure 7.1. CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.2. CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2019)
Figure 8.1. Manufacturing of CD19 CAR-T Cells: Process Comparison
Figure 10.1. Nantes University Hospital’s TIL Therapy: Production Procedure
Figure 11.1. Leukemia: Classification
Figure 11.2. Leukemia: Global Epidemiological Distribution
Figure 11.3. Lymphoma: Global Epidemiological Distribution
Figure 11.4. Multiple Myeloma: Global Epidemiological Distribution
Figure 11.5. Melanoma: Global Epidemiological Distribution
Figure 11.6. Lung Cancers: Classification
Figure 11.7. Lung Cancer: Global Epidemiological Distribution
Figure 11.8. Pancreatic Cancer: Global Epidemiological Distribution
Figure 11.9. Liver Cancer: Global Epidemiological Distribution
Figure 11.10. Breast Cancer: Global Epidemiological Distribution
Figure 11.11. Ovarian Cancer: Global Epidemiological Distribution
Figure 11.12. Bladder Cancer: Global Epidemiological Distribution
Figure 11.13. Kidney Cancer: Global Epidemiological Distribution
Figure 12.1. Genome Editing Technologies: Applications
Figure 12.2. Genome Editing Technologies Used in T-Cell Therapies
Figure 12.3. Competitiveness Analysis: Genome Editing Technologies
Figure 12.4. Key Technologies to Enhance Features / Characteristics of T-Cell Therapies
Figure 12.5. Cellectis: Properties of Enhanced T-Cell Platform
Figure 12.6. Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 13.1. Partnerships and Collaborations: Cumulative Trend by Year, 2005-2019
Figure 13.2. Partnerships and Collaborations: Year-Wise Trend of Industry vs Non-Industry Partnerships, 2005-2019
Figure 13.3. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 13.4. Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2016 and 2016-2019
Figure 13.5. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 13.6. Partnerships and Collaborations: Distribution by Type of Product and Year-Wise Trend
Figure 13.7. Partnerships and Collaborations: Distribution by Type of Industry
Figure 13.8. Partnerships and Collaborations: Distribution by Type of Industry and Type of Product
Figure 13.9. Partnerships and Collaborations: Distribution by Individual Products
Figure 13.10. Most Active Industry Players: Distribution by Number of Partnerships
Figure 13.11. Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 13.12. Most Active Contract Manufacturers: Distribution by Number of Manufacturing Agreements
Figure 13.13. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution of Manufacturing Agreements
Figure 13.14. Partnerships and Collaborations: Regional Distribution
Figure 13.15. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 14.1. Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2009-2019
Figure 14.2. Funding and Investment Analysis: Cumulative Amount Invested, Pre-2009-2019 (USD Million)
Figure 14.3. Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2009-2019
Figure 14.4. Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, Pre-2009-2019 (USD Million)
Figure 14.5. Funding and Investments: Analysis by Amount Invested across Different Types of Therapies
Figure 14.6. Most Active Players: Distribution by Number of Instances
Figure 14.7. Most Active Investors: Distribution by Number of Instances
Figure 14.8. Funding and Investment Analysis: Distribution by Geography
Figure 15.1. Other T-Cell Immunotherapies: Analysis by Phase of Development
Figure 15.2. Other T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Figure 15.3. Other T-Cell Immunotherapies: Analysis by Type of Cells
Figure 15.4. Other T-Cell Immunotherapies: Analysis by Source of T-Cells
Figure 15.5. Treg Cells: Functions
Figure 16.1. Steps for Manufacturing Cell Therapies
Figure 16.2. Centralized Manufacturing: Process Model
Figure 16.3. Decentralized Manufacturing: Process Model
Figure 16.4. Cell Therapy Manufacturing: Types of Manufacturers
Figure 16.5. Cell Therapy: Challenges and Drivers
Figure 16.6. Cell Therapies: Potency as Critical Quality Attribute
Figure 16.7. Cell Therapy Manufacturing: Supply Chain Model
Figure 16.8. Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 17.1. Targeted Therapies: Pricing Model based on Patient Segment
Figure 18.1. Overall T-Cell Immunotherapies Market, 2019-2030 (USD Billion)
Figure 18.2. T-Cell Immunotherapies Market: Distribution by Type of Therapy, 2025 and 2030 (USD Billion)
Figure 18.3. T-Cell Immunotherapies Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Figure 18.4. T-Cell Immunotherapies Market: Distribution by Target Antigen(s), 2025 and 2030 (USD Billion)
Figure 18.5. T-Cell Immunotherapies Market: Distribution by Key Players, 2025 and 2030 (USD Billion)
Figure 18.6. T-Cell Immunotherapies Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Figure 18.7. Overall CAR-T Cell Therapies Market, 2019-2030 (USD Million)
Figure 18.8. CAR-T Cell Therapies Market: Distribution by Target Indication(s) (USD Million)
Figure 18.9. CAR-T Cell Therapies Market: Distribution by Target Antigen(s) (USD Million)
Figure 18.10. CAR-T Cell Therapies Market: Distribution by Key Players (USD Million)
Figure 18.11. CAR-T Cell Therapies Market: Distribution by Target Geography (USD Million)
Figure 18.12. KYMRIAH® (Novartis): Current Status of Development
Figure 18.13. KYMRIAH® (Novartis) Sales Forecast, till 2030 (USD Million)
Figure 18.14. YESCARTA® (Gilead Sciences): Current Status of Development
Figure 18.15. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030 (USD Million)
Figure 18.16. bb2121 (bluebird bio / Celgene): Current Status of Development
Figure 18.17. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030 (USD Million)
Figure 18.18. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen): Current Status of Development
Figure 18.19. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030 (USD Million)
Figure 18.20. MB-CART19.1 (Miltenyi Biotec): Current Status of Development
Figure 18.21. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030 (USD Million)
Figure 18.22. CD19 CAR-T (Sinobioway Cell Therapy): Current Status of Development
Figure 18.23. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030 (USD Million)
Figure 18.24. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec): Current Status of Development
Figure 18.25. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030 (USD Million)
Figure 18.26. AUTO2 (Autolus): Current Status of Development
Figure 18.27. AUTO2 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 18.28. AUTO3 (Autolus): Current Status of Development
Figure 18.29. AUTO3 (Autolus) Sales Forecast, till 2030 (USD Million)
Figure 18.30. GPC3 CAR-T (Shanghai GeneChem): Current Status of Development
Figure 18.31. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030 (USD Million)
Figure 18.32. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 18.33. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 18.34. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology): Current Status of Development
Figure 18.35. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030 (USD Million)
Figure 18.36. CD19 CAR-T (Shanghai Bioray Laboratory): Current Status of Development
Figure 18.37. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030 (USD Million)
Figure 18.38. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Current Status of Development
Figure 18.39. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.40. PCAR-019 (PersonGen BioTherapeutics): Current Status of Development
Figure 18.41. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.42. TBI-1501 (Takara Bio): Current Status of Development
Figure 18.43. TBI-1501 (Takara Bio) Sales Forecast, till 2030 (USD Million)
Figure 18.44. IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Current Status of Development
Figure 18.45. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.46. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech): Current Status of Development
Figure 18.47. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030 (USD Million)
Figure 18.48. BinD19 (Shenzhen BinDeBio): Current Status of Development
Figure 18.49. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030 (USD Million)
Figure 18.50. CARCIK-CD19 (Formula Pharmaceuticals): Current Status of Development
Figure 18.51. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030 (USD Million)
Figure 18.52. EGFR CART (The Beijing Pregene Science and Technology): Current Status of Development
Figure 18.53. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.54. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology): Current Status of Development
Figure 18.55. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030 (USD Million)
Figure 18.56. Overall TCR-based Therapies Market, 2019-2030 (USD Million)
Figure 18.57. TCR-based Therapies Market: Distribution by Target Indication(s) (USD Million)
Figure 18.58. TCR-based Therapies Market: Distribution by Target Antigen(s) (USD Million)
Figure 18.59. TCR-based Therapies Market: Distribution by Key Players (USD Million)
Figure 18.60. TCR-based Therapies Market: Distribution by Target Geography (USD Million)
Figure 18.61. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Current Status of Development
Figure 18.62. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030 (USD Million)
Figure 18.63. IMCgp100 (Immunocore): Current Status of Development
Figure 18.64. IMCgp100 (Immunocore) Sales Forecast, till 2030 (USD Million)
Figure 18.65. TBI-1301 (Takara Bio): Current Status of Development
Figure 18.66. TBI-1301 (Takara Bio) Sales Forecast, till 2030 (USD Million)
Figure 18.67. ALT-801 (Altor Bioscience): Current Status of Development
Figure 18.68. ALT-801 (Altor Bioscience) Sales Forecast, till 2030 (USD Million)
Figure 18.69. JTCR016 (Juno Therapeutics): Current Status of Development
Figure 18.70. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.71. LioCyx (Lion TCR): Current Status of Development
Figure 18.72. LioCyx (Lion TCR) Sales Forecast, till 2030 (USD Million)
Figure 18.73. Overall TIL-based Therapies Market, 2019-2030 (USD Million)
Figure 18.74. TIL-based Therapies Market: Distribution by Target Indication(s) (USD Million)
Figure 18.75. TIL-based Therapies Market: Distribution by Key Players (USD Million)
Figure 18.76. TIL-based Therapies Market: Distribution by Target Geography (USD Million)
Figure 18.77. TILs (Nantes University Hospital): Current Status of Development
Figure 18.78. TILs (Nantes University Hospital) Sales Forecast, till 2030 (USD Million)
Figure 18.79. TILs (Netherlands Cancer Institute): Current Status of Development
Figure 18.80. TILs (Netherlands Cancer Institute) Sales Forecast, till 2030 (USD Million)
Figure 18.81. Lifileucel (LN-144) (Iovance Biotherapeutics): Current Status of Development
Figure 18.82. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.83. LN-145 (Iovance Biotherapeutics): Current Status of Development
Figure 18.84. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030 (USD Million)
Figure 18.85. LTX-315 and TILs (Lytix Biopharma): Current Status of Development
Figure 18.86. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030 (USD Million)
Figure 19.1. Different Channels Used for Promotional Campaigns
Figure 19.2. Promotional / Marketing Strategy: Product Website Analysis
Figure 19.3. Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Figure 19.4. Product Website Analysis: KYMRIAH®, Messages for Healthcare Professionals
Figure 19.5. Product Website Analysis: KYMRIAH®, Messages for Patients
Figure 19.6. Product Website Analysis: KYMRIAH®, Patient Support Program
Figure 19.7. KYMRIAH®, Presence in Conferences
Figure 19.8. Product Website Analysis: YESCARTA®, Messages for Healthcare Professionals
Figure 19.9. Product Website Analysis: YESCARTA®, Messages for Patients
Figure 19.10. Product Website Analysis: YESCARTA®, Kite Konnect™
Figure 19.11. Product Website Analysis: YESCARTA®, Platform for Reporting Adverse Events / Products Complaints and Requesting Medical Information
Figure 19.12. YESCARTA®, Presence in Conferences
Figure 21.1. T-Cell Immunotherapies Market Landscape: Industry Participants
Figure 21.2. T-Cell Immunotherapies Market Landscape: Non-Industry Participants
Figure 21.3. T-Cell Immunotherapies Market Forecast, 2019, 2025 and 2030: Conservative, Base and Optimistic Scenarios (USD Billion)

Table 3.1. Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2. FDA Approved Antibody based Cancer Therapeutics
Table 3.5. Key Characteristics of CAR-T Cells
Table 3.6. Comparison of First and Second-Generation CAR-T Cells
Table 3.7. CD19 CAR-T Cells: Preclinical Results
Table 3.8. Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 3.9. CAR-T Cell and TCR-based Therapies: Key Differences
Table 5.1. T-Cell Immunotherapies: Clinical Pipeline
Table 5.2. T-Cell Immunotherapies: Preclinical Pipeline
Table 6.1. CD19 CAR-T Cell Therapies: Competitive Landscape
Table 6.2. CD19 CAR-T Cell Therapies: Clinical Outcomes
Table 6.3. BCMA CAR-T Cell Therapies: Competitive Landscape
Table 6.4. BCMA CAR-T Cell Therapies: Clinical Outcomes
Table 6.5. Meso CAR-T Cell Therapies: Competitive Landscape
Table 6.6. Meso CAR-T Cell Therapies: Clinical Outcomes
Table 6.7. GD2 CAR-T Cell Therapies: Competitive Landscape
Table 6.8. GD2 CAR-T Cell Therapies: Clinical Outcomes
Table 6.9. CAR-T Cell Immunotherapies: Principle Investigators
Table 6.10. TCR-based Immunotherapies: Principle Investigators
Table 6.11. TIL-based Immunotherapies: Principle Investigators
Table 6.12. CAR-T Cell Therapies: Information on Constructs of Clinical Candidates
Table 7.1. CAR-T Cell Immunotherapies: List of Clinical Trials
Table 8.1. KYMRIAH®: Clinical Studies
Table 8.2. KYMRIAH®: Clinical Trial Endpoints (Acute Lymphoblastic Leukemia)
Table 8.3. KYMRIAH®: Clinical Trial Endpoints (Chronic Lymphocytic Leukemia / Multiple Myeloma / Non-Hodgkin Lymphoma)
Table 8.4. YESCARTA®: Clinical Studies
Table 8.5. YESCARTA®: Clinical Trial Endpoints
Table 8.6. JCAR Series: Molecules in Clinical Development
Table 8.7. JCAR Series: CAR-T Design
Table 8.8. JCAR014: Clinical Studies
Table 8.9. JCAR017: Clinical Studies
Table 8.10. JCAR018: Clinical Studies
Table 8.11. JCAR020: Clinical Studies
Table 8.12. JCAR023: Clinical Studies
Table 8.13. JCAR024: Clinical Studies
Table 8.14. JCARH125: Clinical Studies
Table 8.15. JCAR Series: Clinical Trial Endpoints (Phase I/II / Phase II / Phase III)
Table 8.16. JCAR Series: Clinical Trial Endpoints (Phase I)
Table 8.17. JCAR Series: Dosage Regimen
Table 8.18. bb2121: Clinical Studies
Table 8.19. bb2121: Clinical Trial Endpoints
Table 8.20. LCAR-B38M CAR-T: Clinical Studies
Table 8.21. LCAR-B38M CAR-T: Clinical Trial Endpoints
Table 8.22. Takara Bio’s CD19 CAR-T Cell Therapy: Clinical Studies
Table 8.23. Takara Bio’s CD19 CAR-T Cell Therapy: Clinical Trial Endpoints
Table 8.24. TBI-1501: Dosage Regimen
Table 8.25. AUTO2: Clinical Studies
Table 8.26. AUTO3: Clinical Studies
Table 8.27. Autolus’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.28. Sinobioway Cell Therapy’s CD19 CAR-T Cell Therapy: Clinical Studies
Table 8.29. Sinobioway Cell Therapy’s EPCAM CAR-T Cell Therapy: Clinical Studies
Table 8.30. Sinobioway Cell Therapy’s Dual Targeting CAR-T Cell Therapies: Clinical Trial Endpoints
Table 8.31. Phase I/II or Phase II CAR-T Therapies from the Industry Players
Table 9.1. NY-ESO TCR: Clinical Studies
Table 9.2. MAGE-A10: Clinical Studies
Table 9.3. MAGE A-4: Current Status of Development
Table 9.4. AFP T-Cell: Current Status of Development
Table 9.5. NY-ESO TCR / MAGE A-10: Clinical Trial Endpoints
Table 9.6. MAGE A-10 / MAGE A-4 / AFP TCR: Clinical Trial Endpoints
Table 9.7. IMCgp100: Clinical Studies
Table 9.7. IMCgp100: Clinical Trial Endpoints
Table 9.8. ALT-801: Clinical Studies
Table 9.9. ALT-801: Clinical Trial Endpoints
Table 9.10. JTCR016: Clinical Studies
Table 9.11. JTCR016: Clinical Trial Endpoints
Table 9.12. WT1 TCR: Clinical Studies
Table 9.13. WT1 TCR: Clinical Trial Endpoints
Table 9.14. TBI-1301: Clinical Studies
Table 9.15. TBI-1301: Clinical Trial Endpoints
Table 10.1. LN-144: Current Status of Development
Table 10.2. LN-144: Clinical Trial Endpoints
Table 10.3. LN-144: Patent Portfolio
Table 10.4. LN-145: Current Status of Development
Table 10.5. LN-145: Clinical Trial Endpoints
Table 10.6. Nantes University Hospital’s TIL Therapy: Clinical Trial Endpoints
Table 10.7. Netherlands Cancer Institute’s TIL Therapy: Clinical Trial Endpoints
Table 11.1. Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 11.2. Leukemia: List of Marketed Targeted Therapeutics
Table 11.3. Lymphoma: List of Marketed Targeted Therapeutics
Table 11.4. T-Cell Immunotherapies: Targets under Investigation for Leukemia
Table 11.5. T-Cell Immunotherapies: Targets under Investigation for Lymphoma
Table 11.6. Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 11.7. T-Cell Immunotherapies: Targets under Investigation for Multiple Myeloma
Table 11.8. Melanoma: List of Marketed Targeted Therapeutics
Table 11.9. TIL Therapy: Historical Development of Treatment Protocols for Melanoma at the National Cancer Institute
Table 11.10. T-Cell Immunotherapies: TIL Therapies under Investigation for Metastatic Melanoma
Table 11.11. Lung Cancer: List of Marketed Targeted Therapeutics
Table 11.12. T-Cell Immunotherapies: Targets under Investigation for Lung Cancer
Table 11.13. Pancreatic Cancer: List of Marketed Targeted Therapeutics
Table 11.14. T-Cell Immunotherapies: Targets under Investigation for Pancreatic Cancer
Table 11.15. Liver Cancer: List of Marketed Targeted Therapeutics
Table 11.16. CAR-T Cell Therapies: Targets under Investigation for Liver Cancer
Table 11.17. TCR-based Therapies: Targets under Investigation for Liver Cancer
Table 11.18. Breast Cancer: List of Marketed Targeted Therapeutics
Table 11.19. CAR-T Cell Therapies: Targets under Investigation for Breast Cancer
Table 11.20. TCR-based Therapies: Targets under Investigation for Breast Cancer
Table 11.21. Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 11.22. T-Cell Immunotherapies: Targets under Investigation for Ovarian Cancer
Table 11.23. Bladder Cancer: List of Marketed Targeted Therapeutics
Table 11.24. Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
Table 12.1. Editas Medicine: CRISPR / Cas9 Technology, Research Publications
Table 12.2. Editas Medicine: Funding Instances
Table 12.3. Editas Medicine: Collaborations
Table 12.4. Intellia Therapeutics: CRISPR / Cas9 Technology, Research Publications
Table 12.5. Intellia Therapeutics: Funding Instances
Table 12.6. Intellia Therapeutics: Collaborations
Table 12.7. CRISPR Therapeutics: CRIPSR / Cas9 Technology, Research Publications
Table 12.8. CRISPR Therapeutics: Funding Instances
Table 12.9. CRISPR Therapeutics: Collaborations
Table 12.10. Beam Therapeutics: Funding Instances
Table 12.11. Beam Therapeutics: Collaborations
Table 12.12. Gracell Biotechnologies: Funding Instances
Table 12.13. Cellectis: Funding Instances
Table 12.14. Cellectis: Collaborations
Table 12.15. bluebird bio: megaTAL Technology, Research Publications
Table 12.16. bluebird bio: Funding Instances
Table 12.17. bluebird bio: Collaborations
Table 12.18. Sangamo Therapeutics: Funding Instances
Table 12.19. Sangamo Therapeutics: Collaborations
Table 12.20. Unum Therapeutics: Funding Instances
Table 12.21. Unum Therapeutics: Collaborations
Table 12.22. Celyad: Funding Instances
Table 12.23. Celyad: Collaborations
Table 12.24. Glycostem: Funding Instances
Table 12.25. Glycostem: Collaborations
Table 12.26. Intrexon: Funding Instances
Table 12.27. Intrexon: Collaborations
Table 12.28. Bellicum Pharmaceuticals: Key Switch Technologies
Table 12.29. Bellicum Pharmaceuticals: Switch Technologies, Research Publications
Table 12.30. Bellicum Pharmaceuticals: Funding Instances
Table 12.31. Bellicum Pharmaceuticals: Collaborations
Table 12.32. Theravectys: Funding Instances
Table 12.33. CAR-T Cell Therapy Technologies for Safety Enhancement
Table 12.34. Formula Pharmaceuticals: Collaborations
Table 13.1. T-Cell Immunotherapies: Partnerships and Collaborations, 2005-2019
Table 14.1. T-Cell Immunotherapies: Funding and Investments, Pre-2009-2017
Table 14.2. T-Cell Immunotherapies: Summary of Investments
Table 15.1. List of Other T-Cell Immunotherapies
Table 15.2. Treg Cells: Properties
Table 16.1. Assessment Strategies for Different Manufacturing Processes
Table 16.2. Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 16.3. Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 16.4. Cell Therapy Manufacturing: Contract Manufacturers
Table 17.1. Price of Marketed Cell / Gene Therapies
Table 17.2. Price of Marketed Targeted Drugs
Table 17.3. T-Cell Immunotherapies: Expert Opinions on Pricing
Table 17.4. CAR-T Cell Therapies: Reimbursement Landscape
Table 18.1. T-Cell Immunotherapies: List of Forecasted Molecules
Table 18.2. T-Cell Immunotherapies Market: Value Creation Analysis
Table 19.1. KYMRIAH®: Drug Overview
Table 19.2. YESCARTA®: Drug Overview
Table 20.1. Adaptimmune Therapeutics: Company Profile
Table 20.2. Autolus: Company Profile
Table 20.3. bluebird bio: Company Profile
Table 20.4. CARsgen Therapeutics: Company Profile
Table 20.5. Celgene: Company Profile
Table 20.6. Cell Medica: Company Profile
Table 20.7. Cellectis: Company Profile
Table 20.8. Cellular Biomedicine Group: Company Profile
Table 20.9. Immunocore: Company Profile
Table 20.10. Innovative Cellular Therapeutics: Company Profile
Table 20.11. Iovance Biotherapeutics: Company Profile
Table 20.12. Kite Pharma: Company Profile
Table 20.13. Lion TCR: Company Profile
Table 20.14. Noile-Immune Biotech: Company Profile
Table 20.15. Novartis: Company Profile
Table 20.16. Shanghai GeneChem: Company Profile
Table 20.17. Sinobioway Cell Therapy: Company Profile
Table 20.18. Takara Bio: Company Profile
Table 20.19. Unum Therapeutics: Company Profile
Table 20.20. ZIOPHARM Oncology: Company Profile
Table 23.1. T-Cell Immunotherapies: Analysis by Type of Product
Table 23.2. T-Cell Immunotherapies: Analysis by Type of Developer
Table 23.3. T-Cell Immunotherapies: Analysis by Type of Developer and Type of Product
Table 23.4. T-Cell Immunotherapies: Analysis by Phase of Development
Table 23.5. T-Cell Immunotherapies: Analysis by Phase of Development and Type of Product
Table 23.6. T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Table 23.7. T-Cell Immunotherapies: Analysis by Target Therapeutic Area and Type of Product
Table 23.8. T-Cell Immunotherapies: Analysis by Popular Target Indications
Table 23.9. CAR-T Cell Immunotherapies: Analysis by Popular Target Indications
Table 23.10. TCR-based Immunotherapies: Analysis by Popular Target Indications
Table 23.11. TIL-based Immunotherapies: Analysis by Popular Target Indications
Table 23.12. CAR-T Cell Immunotherapies: Analysis by Target Antigen
Table 23.13. TCR-based Immunotherapies: Analysis by Target Antigen
Table 23.14. T-Cell Immunotherapies: Analysis by Source of T-Cells
Table 23.15. T-Cell Immunotherapies: Analysis by Source of T-Cells and Type of Product
Table 23.16. T-Cell Immunotherapies: Analysis by Route of Administration
Table 23.17. T-Cell Immunotherapies: Analysis by Route of Administration and Type of Product
Table 23.18. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Clinical Development
Table 23.19. T-Cell Immunotherapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 23.20. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Table 23.21. T-Cell Immunotherapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Table 23.22. T-Cell Immunotherapies: Popular Targets in Hematological Malignancies
Table 23.23. T-Cell Immunotherapies: Popular Targets in Solid Tumor
Table 23.24. CAR-Construction: Analysis by Generation of CAR-T Therapies
Table 23.25. CAR-Construction: Analysis by Type scFv Antibody used in CAR-T Therapies
Table 23.26. CAR-Construction: Analysis by Type of Vector
Table 23.27. CAR-Construction: Analysis by Type of Co-Stimulatory Domain(s)
Table 23.28. CAR-T Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Table 23.29. CAR-T Cell Therapy Clinical Trials: Distribution by Number of Clinical Trials and Geography (Pre-2016 and 2019)
Table 23.30. Partnerships and Collaborations: Cumulative Trend by Year, 2005-2019
Table 23.31. Partnerships and Collaborations: Year-Wise Trend of Industry vs Non-Industry Partnerships, 2005-2019
Table 23.32. Partnerships and Collaborations: Distribution by Type of Partnership
Table 23.33. Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2016 and 2016-2019
Table 23.34. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 23.35. Partnerships and Collaborations: Distribution by Type of Product and Year-Wise Trend
Table 23.36. Partnerships and Collaborations: Distribution by Type of Industry
Table 23.37. Partnerships and Collaborations: Distribution by Type of Industry and Type of Product
Table 23.38. Partnerships and Collaborations: Distribution by Individual Products
Table 23.39. Most Active Industry Players: Distribution by Number of Partnerships
Table 23.40. Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 23.41. Most Active Contract Manufacturers: Distribution by Number of Manufacturing Agreements
Table 23.42. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution of Manufacturing Agreements
Table 23.43. Partnerships and Collaborations: Regional Distribution
Table 23.44. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 23.45. Funding and Investment Analysis: Cumulative Number of Instances by Year, Pre-2009-2019
Table 23.46. Funding and Investment Analysis: Cumulative Amount Invested, Pre-2009-2019 (USD Million)
Table 23.47. Funding and Investment Analysis: Distribution of Instances by Type of Funding, Pre-2009-2019
Table 23.48. Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, Pre-2009-2019 (USD Million)
Table 23.49. Funding and Investments: Analysis by Amount Invested across Different Types of Therapies
Table 23.50. Most Active Players: Distribution by Number of Instances
Table 23.51. Most Active Investors: Distribution by Number of Instances
Table 23.52. Funding and Investment Analysis: Distribution by Geography
Table 23.53. Other T-Cell Immunotherapies: Analysis by Phase of Development
Table 23.54. Other T-Cell Immunotherapies: Analysis by Target Therapeutic Area
Table 23.55. Other T-Cell Immunotherapies: Analysis by Type of Cells
Table 23.56. Other T-Cell Immunotherapies: Analysis by Source of T-Cells
Table 23.57. Overall T-Cell Immunotherapies Market, 2019-2030: Conservative Scenario (USD Billion)
Table 23.58. Overall T-Cell Immunotherapies Market, 2019-2030: Base Scenario (USD Billion)
Table 23.59. Overall T-Cell Immunotherapies Market, 2019-2030: Optimistic Scenario (USD Billion)
Table 23.60. T-Cell Immunotherapies Market: Distribution by Type of Therapy, 2025 and 2030 (USD Billion)
Table 23.61. T-Cell Immunotherapies Market: Distribution by Target Indication(s), 2025 and 2030 (USD Billion)
Table 23.62. T-Cell Immunotherapies Market: Distribution by Target Antigen(s), 2025 and 2030 (USD Billion)
Table 23.63. T-Cell Immunotherapies Market: Distribution by Key Players, 2025 and 2030 (USD Billion)
Table 23.64. T-Cell Immunotherapies Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 23.65. Overall CAR-T Cell Therapies Market, 2019-2030: Conservative Scenario (USD Million)
Table 23.66. Overall CAR-T Cell Therapies Market, 2019-2030: Base Scenario (USD Million)
Table 23.67. Overall CAR-T Cell Therapies Market, 2019-2030: Optimistic Scenario (USD Million)
Table 23.68. CAR-T Cell Therapies Market: Distribution by Target Indications (USD Million)
Table 23.69. CAR-T Cell Therapies Market: Distribution by Target Antigens (USD Million)
Table 23.70. CAR-T Cell Therapies Market: Distribution by Key Players (USD Million)
Table 23.71. CAR-T Cell Therapies Market: Distribution by Target Geography (USD Million)
Table 23.72. KYMRIAH® (Novartis) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.73. KYMRIAH® (Novartis) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.74. KYMRIAH® (Novartis) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.75. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.76. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.77. YESCARTA® (Gilead Sciences) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.78. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.79. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.80. bb2121 (bluebird bio / Celgene) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.82. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.83. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.84. LCAR-B38M CAR-T (Nanjing Legend Biotech / Janssen) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.85. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.86. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.87. MB-CART19.1 (Miltenyi Biotec) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.88. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.89. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.90. CD19 CAR-T (Sinobioway Cell Therapy) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.91. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.92. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.93. JCAR017 (Juno Therapeutics / Celgene / WuXi AppTec) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.94. AUTO2 (Autolus) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.95. AUTO2 (Autolus) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.96. AUTO2 (Autolus) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.97. AUTO3 (Autolus) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.98. AUTO3 (Autolus) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.99. AUTO3 (Autolus) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.100. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.101. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.102. GPC3 CAR-T (Shanghai GeneChem) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.103. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.104. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.105. BCMA CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.106. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.107. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.108. CD19 CAR-T (The Pregene (ShenZhen) Biotechnology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.109. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.110. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.111. CD19 CAR-T (Shanghai Bioray Laboratory) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.112. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.113. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.114. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.115. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.116. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.117. PCAR-019 (PersonGen BioTherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.118. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.119. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.120. TBI-1501 (Takara Bio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.121. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.122. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.123. IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.124. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.125. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.126. CCT301 CAR-T (Shanghai Sinobioway Sunterra Biotech) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.127. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.128. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.129. BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.130. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.131. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.132. CARCIK-CD19 (Formula Pharmaceuticals) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.133. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.134. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.135. EGFR CART (The Beijing Pregene Science and Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.136. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.137. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.138. Anti-MUC1 CAR-T (Guangzhou Anjie Biomedical Technology) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.139. Overall TCR-based Therapies Market, 2019-2030: Conservative Scenario (USD Million)
Table 23.140. Overall TCR-based Therapies Market, 2019-2030: Base Scenario (USD Million)
Table 23.141. Overall TCR-based Therapies Market, 2019-2030: Optimistic Scenario (USD Million)
Table 23.142. TCR-based Therapies Market: Distribution by Target Indications (USD Million)
Table 23.143. TCR-based Therapies Market: Distribution by Target Antigens (USD Million)
Table 23.144. TCR-based Therapies Market: Distribution by Key Players (USD Million)
Table 23.145. TCR-based Therapies Market: Distribution by Target Geography (USD Million)
Table 23.146. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.147. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.148. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.149. IMCgp100 (Immunocore) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.150. IMCgp100 (Immunocore) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.151. IMCgp100 (Immunocore) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.152. TBI-1301 (Takara Bio) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.153. TBI-1301 (Takara Bio) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.154. TBI-1301 (Takara Bio) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.155. ALT-801 (Altor Bioscience) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.156. ALT-801 (Altor Bioscience) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.157. ALT-801 (Altor Bioscience) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.158. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.159. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.160. JTCR016 (Juno Therapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.161. LioCyx (Lion TCR) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.162. LioCyx (Lion TCR) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.163. LioCyx (Lion TCR) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.164. Overall TIL-based Therapies Market, 2019-2030: Conservative Scenario (USD Million)
Table 23.165. Overall TIL-based Therapies Market, 2019-2030: Base Scenario (USD Million)
Table 23.166. Overall TIL-based Therapies Market, 2019-2030: Optimistic Scenario (USD Million)
Table 23.167. TIL-based Therapies Market: Distribution by Target Indication(s) (USD Million)
Table 23.168. TIL-based Therapies Market: Distribution by Key Players (USD Million)
Table 23.169. TIL-based Therapies Market: Distribution by Target Geography (USD Million)
Table 23.170. TILs (Nantes University Hospital) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.171. TILs (Nantes University Hospital) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.172. TILs (Nantes University Hospital) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.173. TILs (The Netherlands Cancer Institute) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.174. TILs (The Netherlands Cancer Institute) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.175. TILs (The Netherlands Cancer Institute) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.176. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.177. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.178. Lifileucel (LN-144) (Iovance Biotherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.179. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.180. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.181. LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2030: Optimistic Scenario (USD Million)
Table 23.182. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030: Conservative Scenario (USD Million)
Table 23.183. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030: Base Scenario (USD Million)
Table 23.184. LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2030s: Optimistic Scenario (USD Million)
Table 23.185. T-Cell Immunotherapies Market Forecast, 2019, 2025, 2030: Conservative, Base and Optimistic Scenarios (USD Billion)